Loading
Kamada Ltd Stock: price and insider trades · United States
US·Mcap US$443.8M
Kamada Ltd: what insiders have been doing
Kamada Ltd is a listed company. Its directors and officers file their transactions with SEC (Form 4). From 21 October 2025 to 21 October 2026, the disclosure feed for Kamada Ltd logged 20 filings by 3 insiders.
All open-market trades in the period are sales: 4 sales worth €1.4M, by 1 insider, with no purchase on record. One trade stands out by size: a sale of €1.2M from Tsur David, disclosed on 11 September 2026, or 0.29% of market capitalisation.
Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 20 filings here. Over the whole record (from 2026), the tally stands at no purchases and 4 sales. The 20-F for the year ended 31 December 2025 shows 180.5 m USD of revenue and 20.2 m USD of net income.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
20
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€1M
4 ops. · all time
Who traded when
BuySaleDavid Tsur4 sales
Analyst consensus: bullish or bearish?
Analysts rate Kamada Ltd Strong Buy (bullish), based on 4 analysts. Average price target: US$13.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,587 of 26,272 companies
62.2
score / 100
Value55
Quality70
FCF yld3.5%
Earn yld4.5%
EV/EBITDA11.8x
ROE8.4%
Gross mgn42%
Net mgn11%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.69
Analyst consensus
4 analystsStrong buy
US$11.00Target US$13.50(+76%)US$15.00
Income statement
RevenueUS$180.5M
Gross profitUS$76.4M42% margin
EBITDAUS$39.2M22% margin
Net incomeUS$20.2M11.6% margin
Valuation
PER (trailing)20.2x
PER (forward)13.3x
P/Book1.7x
Beta0.13
Balance sheet & cash
Market capUS$443.8M
Total debtUS$11.6M
Free Cash FlowUS$15.6M
Debt / Equity4%
Profitability & ownership
ROE8.4%
ROA4.6%
% insiders7.0%
% institutions49.2%
Last declaration on 17 September 2026
Declarations20 total
5,000 shares@ US$5.930.0058% mcap11.8% of flowOrdinary SharesSEC:0001213900-26-100845:0
1,371 shares@ US$8.360.0022% mcap4.6% of flowOrdinary SharesSEC:0001213900-26-100845:1
5,464 shares@ US$5.930.0063% mcap12.9% of flowOrdinary SharesSEC:0001213900-26-100845:8
22,827 shares@ US$8.180.036% mcap9.1% of flowOrdinary SharesSEC:0001213900-26-100839:0
10,000 shares@ US$5.370.010% mcap65.0% of flowOrdinary SharesSEC:0001213900-26-100842:0
3,459 shares@ US$8.350.0056% mcap35.0% of flowOrdinary SharesSEC:0001213900-26-100842:1
6,500 shares@ US$5.930.0075% mcap15.4% of flowOrdinary SharesSEC:0001213900-26-100845:6
1,783 shares@ US$8.360.0029% mcap6.0% of flowOrdinary SharesSEC:0001213900-26-100845:7
1,499 shares@ US$8.350.0024% mcap5.0% of flowOrdinary SharesSEC:0001213900-26-100845:9
14,238 shares@ US$8.280.023% mcap5.7% of flowOrdinary SharesSEC:0001213900-26-099060:0
162,760 shares@ US$8.260.26% mcap65.3% of flowOrdinary SharesSEC:0001213900-26-099060:1
175 shares@ US$8.260.0003% mcap0.1% of flowOrdinary SharesSEC:0001213900-26-099060:2
26,500 shares@ US$7.360.038% mcap9.5% of flowOrdinary SharesSEC:0001213900-26-097829:0
2,760 shares@ US$8.300.0045% mcap1.1% of flowOrdinary SharesSEC:0001213900-26-097829:1
22,500 shares@ US$5.940.026% mcap6.5% of flowOrdinary SharesSEC:0001213900-26-097829:2
6,406 shares@ US$8.260.010% mcap2.6% of flowOrdinary SharesSEC:0001213900-26-097829:3
3,036 shares@ US$5.940.0035% mcap7.2% of flowOrdinary SharesSEC:0001213900-26-097830:0
865 shares@ US$8.370.0014% mcap2.9% of flowOrdinary SharesSEC:0001213900-26-097830:1
10,000 shares@ US$6.250.012% mcap24.8% of flowOrdinary SharesSEC:0001213900-26-095332:0
2,776 shares@ US$8.580.0046% mcap9.4% of flowOrdinary SharesSEC:0001213900-26-095332:1
20 of 20 declarations
About Kamada Ltd
Kamada Ltd is a biopharmaceutical company focused on the development and commercialization of therapeutic products based on proteins. It is listed on NASDAQ.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
